Nebivolol Biogaran (Nebivolol)

Nebivolol belongs to the beta‑blocker class and is indicated for cardiovascular conditions where reduction of sympathetic activity is required.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Heart failure: improves left‑ventricular ejection fraction and decreases hospitalization rates.
• Elevated blood pressure in patients with diabetes: helps achieve target blood pressure while offering metabolic neutrality.

• Nebivolol selectively blocks β1‑adrenergic receptors in cardiac tissue, reducing heart rate and contractility. In addition, it stimulates endothelial nitric oxide synthase, causing nitric‑oxide‑mediated vasodilation, which further contributes to blood‑pressure reduction without significant β2 blockade.

Nebivolol is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or light‑headedness, especially on standing.
• Fatigue or tiredness during initial therapy.
• Nausea or mild gastrointestinal upset.
• Bradycardia: heart rate slower than normal.
• Nasal congestion or sinusitis.

Serious or Rare Side Effects

• Severe bradycardia or heart block requiring medical attention.
• Acute bronchospasm in patients with asthma or COPD.
• Allergic reactions such as rash, itching, or angioedema.
• Hepatic dysfunction manifested by elevated liver enzymes.
• Cardiogenic shock in patients with decompensated heart failure.

Nebivolol requires careful assessment before and during therapy.

• Blood pressure monitoring: ensure target levels are reached without excessive drop.
• Cardiac function evaluation: baseline ECG and periodic checks for bradycardia.
• Respiratory caution: avoid in uncontrolled asthma or severe COPD.
• Renal impairment: dose adjustment may be needed in moderate to severe dysfunction.
• Discontinuation: taper gradually to prevent rebound hypertension.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, requiring clinical vigilance.

Major Interactions (Avoid)

• Other beta‑blockers: additive negative chronotropic effects.
• Calcium‑channel blockers verapamil or diltiazem: may cause profound bradycardia or AV block.
• Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase nebivolol plasma concentrations.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance antihypertensive effect, risking hypotension.
• ACE inhibitors or ARBs: combined use can improve blood‑pressure control but requires monitoring of renal function.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response.
• Antidiabetic agents: monitor blood glucose as beta‑blockade can mask hypoglycemia symptoms.
• Antidepressants (other than CYP2D6 inhibitors): watch for additive central nervous system effects.